Quarterly Result7 Nov 2025, 08:42 pm
Aarti Drugs Q2 & H1 FY26: Revenue Grows 9% YoY to Rs. 652.9 Crore, PAT Up 29% YoY
AI Summary
Aarti Drugs Limited, a Mumbai-based pharmaceutical company, has reported its unaudited financial results for the quarter and half year ended 30th September 2025. The company's revenue for Q2 FY26 stood at Rs. 652.9 crore, up 9% YoY, driven by favorable export volumes. EBITDA for the same period was Rs. 84.4 crore, a 23% YoY increase, with an EBITDA margin of 12.9%. Profit After Tax (PAT) stood at Rs. 45.2 crore, a 29% YoY increase, translating to a PAT margin of 6.9%. For H1 FY26, revenue was Rs. 1,243.7 crore, up 8% YoY, with EBITDA at Rs. 158.8 crore, up 18% YoY, and PAT at Rs. 99.1 crore, up 45% YoY.
Key Highlights
- Revenue for Q2 FY26 stood at Rs. 652.9 crore, up 9% YoY
- EBITDA for Q2 FY26 was Rs. 84.4 crore, up 23% YoY
- PAT for Q2 FY26 was Rs. 45.2 crore, up 29% YoY
- H1 FY26 revenue was Rs. 1,243.7 crore, up 8% YoY
- H1 FY26 EBITDA was Rs. 158.8 crore, up 18% YoY
- H1 FY26 PAT was Rs. 99.1 crore, up 45% YoY